Search research articles
Contact Us
Filters
Showing results (171-180 of 189) with videos related to
Page
of 19
Sort By:
Blood Neoplasia
|
September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Blood
|
November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML
Warren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Blood
|
April 27, 2019
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
American Journal of Hematology
|
October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
Nicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
Blood Cancer Journal
|
March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
Hemasphere
|
January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
Blood
|
February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors
Dyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Jayastu Senapati, Warren C Fiskus, Naval Daver, et al.
Blood
|
March 31, 2025
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML
Zhe Wang, Anna Skwarska, Gowri Poigaialwar, et al.
Leukemia
|
December 22, 2018
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML
Dyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 189) with videos related to
Sort By:
Page
of 19
Blood Neoplasia
|
September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Blood
|
November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML
Warren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Blood
|
April 27, 2019
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
American Journal of Hematology
|
October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
Nicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
Blood Cancer Journal
|
March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
Hemasphere
|
January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
Blood
|
February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors
Dyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Jayastu Senapati, Warren C Fiskus, Naval Daver, et al.
Blood
|
March 31, 2025
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML
Zhe Wang, Anna Skwarska, Gowri Poigaialwar, et al.
Leukemia
|
December 22, 2018
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML
Dyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Page
of 19